Literature DB >> 30530292

Multiple myeloma in paleopathology: A critical review.

Giulia Riccomi1, Gino Fornaciari2, Valentina Giuffra2.   

Abstract

This paper provides a critical literature review concerning paleopathological evidence of multiple myeloma discovered both in the Old and in the New World. A critical assessment of the bioarchaeological and paleopathological documentary sources permitted to identify a total of 25 ascertained cases of multiple myeloma from different geographical areas in the world ranging from Prehistoric times up to the Contemporary age. The distribution of multiple myeloma findings in past times shows that the majority of cases have been discovered in the Old World (n = 18) and extend back to the Middle Ages, while the evidences in the New World (n = 7) seems to date back to the pre-Columbian era. The demographic profile suggests a sex ratio of 1.3:1, while 91.7% of affected individuals (n = 24) are adults. This critical review also discusses the diagnostic criteria and methodological issues commonly attempted in paleo-oncological research, with particular regard to the differential diagnosis of multiple myeloma. As such, the main focus of this work is to present a comprehensive and exhaustive scrutiny of the skeletal manifestations identified as multiple myeloma in order to improve the accuracy of diagnoses within the field of paleopathology.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; Differential diagnosis; Haematology; New World; Old World

Mesh:

Year:  2018        PMID: 30530292     DOI: 10.1016/j.ijpp.2018.12.001

Source DB:  PubMed          Journal:  Int J Paleopathol        ISSN: 1879-9817            Impact factor:   1.393


  5 in total

1.  PLK4 inhibitor plus bortezomib exhibits a synergistic effect on treating multiple myeloma via inactivating PI3K/AKT signaling.

Authors:  Biao Xu; Jingyuan Li; Dehong Xu; Qijie Ran
Journal:  Ir J Med Sci       Date:  2022-05-04       Impact factor: 1.568

2.  lncRNA transcription factor 7 is related to deteriorating clinical features and poor prognosis in multiple myeloma, and its knockdown suppresses disease progression by regulating the miR-203-mediated Jagged1-Notch1 signaling pathway.

Authors:  Haiyan Liu; Yaodong Shen; Ya Xu; Li Wang; Chenlu Zhang; Yijing Jiang; Lemin Hong; Hongming Huang; Hong Liu
Journal:  Oncol Lett       Date:  2021-03-22       Impact factor: 2.967

3.  Deep Learning-Based CT Imaging in Diagnosing Myeloma and Its Prognosis Evaluation.

Authors:  Jinzhou Wang; Xiangjun Shi; Xingchen Yao; Jie Ren; Xinru Du
Journal:  J Healthc Eng       Date:  2021-09-13       Impact factor: 2.682

Review 4.  Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma.

Authors:  Waqqas Tai; Ahsan Wahab; Diana Franco; Zunairah Shah; Aqsa Ashraf; Qurrat-Ul-Ain Abid; Yaqub Nadeem Mohammed; Darshan Lal; Faiz Anwer
Journal:  Antibodies (Basel)       Date:  2022-03-24

5.  Tumor immune cell infiltration score based model predicts prognosis in multiple myeloma.

Authors:  Can Chen; Yiwei Li; Peiwen Miao; Ying Xu; Yaping Xie; Zhenzhen Chen; Shenxian Qian
Journal:  Sci Rep       Date:  2022-10-12       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.